UK relies on EMA’s review of Xgeva reformulation in first-ever reciprocal approval

For the first time since Brexit, the UK’s medicines regulator has made use of its new approval pathway that can speed drug approvals based on the work of regulators in other countries.

In this case, the UK’s MHRA is relying on the work of the European Medicines Agency to sign…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks